Clinical trialPhase 1 / Phase 2Not yet recruiting
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 10 September 2026
- Expected end
- 1 May 2029
- Enrollment
- 45 participants
- Sites
- 1
- Primary outcomes
- Recommended Phase II Dose (RP2D); Objective Response Rate (ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 3 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try